App-Quantinova.ai

ADALIMUMAB INTRODUCTION VERSUS METHOTREXATE DOSE ESCALATION IN PATIENTS WITH INADEQUATELY CONTROLLED PSORIATIC ARTHRITIS: RESULTS FROM RANDOMIZED PHASE 4 CONTROL STUDY

L. C. Coates - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

Methotrexate

ADDITIONAL BENEFIT OF ULTRASOUND TO THE EARLY DIAGNOSIS OF PSORIATIC ARTHRITIS

Y. Geng - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Inflammatory Arthritis

N/A

ADVANCED MICROCIRCULATORY DAMAGE IS ASSOCIATED WITH INCREASED PULSE WAVE REFLECTIONS IN PATIENTS WITH SSC

E. Pagkopoulou - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

AGREEMENT BETWEEN PATIENT-REPORTED OUTCOME MEASURES COLLECTED VIA A SMARTPHONE APPLICATION VS A TOUCHSCREEN SOLUTION IN AN OUTPATIENT CLINIC AMONG PATIENTS WITH INFLAMMATORY ARTHRITIS: A RANDOMISED, WITHIN-PARTICIPANT TRIAL

L. Uhrenholt - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Axial spondyloarthritis

N/A

ALTERATIONS OF THE FECAL MICROBIOTA ASSOCIATED WITH EXACERBATION OF LUPUS ACTIVITY BY HCMV PP65 422-439 IMMUNIZATION IN NZB/W F1 MICE

Y. C. Tsai - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

AN AUDIT OF GLUCOCORTICOID PRESCRIPTION IN PATIENTS WITH GIANT CELL ARTERITIS

H. H. Ariff - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Giant cell arteritis

Glucocorticoid

AN AUDIT OF ORIGINATOR ADALIMUMAB TO BIOSIMILAR SWITCH IN TWO HOSPITALS

R. Mazumder - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Adalimumab

AN AGENT-BASED SIMULATION OF THE EFFECTS OF VARYING TIME TO TREATMENT WITH BIOLOGICAL AGENTS ON PATIENT HEALTH AND COST IN AXIAL SPONDYLOARTHRITIS USING NATIONAL REGISTER DATA

A. Roach - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Early inflammatory arthritis

N/A

AN EXPLORATION INTO THE CONVERSATIONS AROUND SEXUAL FUNCTIONING THAT MALES WITH SJÖGREN’S SYNDROME HAVE ON AN INTERNET FORUM.

J. Mccready - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

N/A

AN EXPLANTION FOR HOW VIRAL INFECTION MAY TRIGGER SPONDYLOARTHROPATHY BASED ON TLR9 DRIVEN TNF RESPONSES FROM ENTHESEAL DERIVED PLASMACYTOID DENDRITIC CELLS

Q. Zhou - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Spondyloarthritis

N/A

ANTI-CCP NEGATIVE PATIENTS WITH NEW MUSCULOSKELETAL SYMPTOMS: IMPROVING REFERRALS FROM PRIMARY CARE

L. Garcia-Montoya - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Carbenoxolone sodium

ANTI-NEUTROPHIL CYTOPLASMATIC ANTIBODIES PREDATE SYMPTOM ONSET OF ANCA-ASSOCIATED VASCULITIS. A CASE-CONTROL STUDY

E. Berglin - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Wegener's granulomatosis

N/A

ANTIBODIES AGAINST CYTOSOLIC 5’-NUCLEOTIDASE 1A IN SPORADIC INCLUSION BODY MYOSITIS: ASSOCIATION WITH CLINICAL AND MRI FEATURES

R. Dejthevaporn - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Inclusion body myositis

N/A

ANXIETY AND DEPRESSION IN PSORIATIC ARTHRITIS (PsA) - PREVALENCE AND IMPACT ON PATIENT REPORTED OUTCOMES: REAL-WORLD SURVEY IN THE US AND EUROPE

L. Gossec - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Psoriatic arthritis

N/A

APPS TARGETING SYMPTOMS ASSOCIATED WITH SJÖGREN’S SYNDROME AND POTENTIAL USERS’ PERCEPTIONS OF THEIR FEATURES: CONTENT ANALYSIS AND THINK ALOUD STUDY

C. Mccallum - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Sjogren's syndrome

N/A

ARE WE MISSING CASES OF HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)? A FIVE YEAR RETROSPECTIVE SERVICE EVALUATION OF RECOGNITION AND RESPONSE TO FERRITIN >10,000MG/L IN THE ADULT POPULATION OF A LARGE UK HOSPITAL TRUST

L. Kitchen - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hemophagocytic lymphohistiocytosis

N/A

ASSESSING THE EFFECT OF INCREASED BODY MASS INDEX ON RESPONSE TO TNF INHIBITORS IN ESTABLISHED RHEUMATOID ARTHRITIS: RESULTS FROM THE METEOR DATABASE

M. Dey - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Rheumatoid arthritis

Adalimumab

ASSESSING THE PATIENT EXPERIENCE OF LUPUS NEPHRITIS: DEVELOPMENT OF A CONCEPTUAL MODEL AND REVIEW OF EXISTING PATIENT-REPORTED OUTCOME (PRO) MEASURES

P. Berry - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus nephritis

N/A

ASSESSING THE EFFECT OF INTERVENTIONS FOR AXIAL SPONDYLOARTHRITIS ACCORDING TO THE ENDORSED ASAS/OMERACT CORE OUTCOME SET: A META-RESEARCH STUDY OF TRIALS INCLUDED IN COCHRANE REVIEWS

R. Asmussen Andreasen - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

ASSESSMENT OF FATIGUE IN ADULTS WITH MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A QUALITATIVE STUDY TO EXPLORE WHAT PATIENTS FEEL SHOULD BE MEASURED IN CLINICAL TRIALS

S. Mannix - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Filters

45280 Abstracts